Last updated: February 5, 2026
What is the current status of clinical trials for BARHEMSYS?
BARHEMSYS (amisulpride) was approved by the U.S. Food and Drug Administration (FDA) on December 2, 2020, for preventing postoperative nausea and vomiting (PONV) in adult patients. The initial approval was based on data from two pivotal clinical trials, involving a total of approximately 1,200 patients. These studies demonstrated a significant reduction in PONV incidence compared to placebo, with a favorable safety profile.
No recent updates indicate ongoing phase 3 or phase 4 trials, suggesting the drug’s primary clinical development phase is complete. The focus has shifted to post-market surveillance, drug positioning strategies, and label expansion efforts.
How does the market landscape for antiemetics influence BARHEMSYS?
The global antiemetic market was valued at approximately US$4.73 billion in 2021 and is projected to reach US$6.8 billion by 2028, with a compound annual growth rate (CAGR) of 6.2 percent (Source: Research and Markets). Key segments include nausea and vomiting therapies associated with chemotherapy, surgery, pregnancy, and other conditions.
In the postoperative setting, the market for PONV management is highly competitive, dominated by drugs like ondansetron (Zofran), dexamethasone, and promethazine. However, these agents have limitations, such as variable efficacy, contraindications, and side effects like QT prolongation (ondansetron) or sedation.
BARHEMSYS addresses unmet needs by offering a non-opioid, selectively selective central dopamine D2/D3 receptor antagonist with a favorable safety profile. Its approval for PONV provides an alternative for patients contraindicated for existing therapies.
What is the market penetration and commercial strategy for BARHEMSYS?
Initial launch in the United States targeted hospitals and outpatient surgery centers, leveraging an existing distribution network from its partner, Acacia Pharma. The drug's pricing strategy aligned with premium antiemetic agents, roughly US$50–$60 per dose, reflecting its clinical benefits and novel mechanism.
Market penetration remains limited, with estimated sales of approximately US$10–15 million in its first full year (2021–2022). Barriers include competition with well-established agents, lack of direct head-to-head trials, and limited awareness among clinicians.
Sales momentum depends on expanding indications, increasing clinician familiarity, and potential reimbursement improvements. The company has initiated educational programs targeting anesthesiologists and surgical teams.
What are the projections for BARHEMSYS’s growth in the coming years?
Considering the current market and clinical landscape, projections estimate US$50–$100 million in annual sales by 2025, assuming successful expansion into other indications like chemotherapy-induced nausea or in-patient settings (Source: Evaluate Pharma).
Expansion strategies involve:
- Conducting head-to-head comparative trials with first-line agents.
- Pursuing FDA label expansion for broader antiemetic indications.
- Enhancing dosing options, especially for outpatient procedures.
- Collaborating with hospital formularies for inclusion.
Factors that could influence growth include competitive pressures, regulatory challenges, and market acceptance.
What regulatory developments might impact BARHEMSYS’s future?
Besides the initial approval, no significant regulatory changes are announced. The company may seek additional approvals or label expansions in other jurisdictions, particularly in Europe and Asia, where unmet medical needs for PONV exist.
Future clinical trials could include:
- Study of efficacy in pediatric populations.
- Trials to support indications for chemotherapy-related nausea.
- Evaluation of combination therapies with other antiemetics to improve efficacy.
Regulatory agencies may also impose safety monitoring updates, especially as post-market data accumulates.
Key Takeaways
- BARHEMSYS received FDA approval in 2020 for PONV prevention in adults based on two pivotal trials.
- The global antiemetic market grows at approximately 6.2% annually, with existing agents dominating the PONV segment.
- Current sales are limited but expected to increase to US$50–$100 million by 2025, driven by label expansion and clinical adoption.
- Challenges include competition, clinician awareness, and reimbursement considerations.
- Future growth depends on further clinical trials, geographic expansion, and strategic partnerships.
FAQs
1. What are the primary benefits of BARHEMSYS over existing antiemetics?
It offers selective dopamine receptor antagonism with a favorable safety profile, particularly lacking QT prolongation risks associated with some agents like ondansetron. Its non-sedating profile makes it suitable for outpatient settings.
2. Are there ongoing trials for expanding BARHEMSYS’s indications?
No publicly announced trials are ongoing at this time. Future plans may include trials for chemotherapy-induced nausea or pediatric use.
3. How does BARHEMSYS compare cost-wise to other antiemetics?
Pricing per dose is in the US$50–$60 range, comparable to certain branded agents like ondansetron but higher than generic options, reflecting its novel mechanism and safety profile.
4. What obstacles hinder market penetration of BARHEMSYS?
Limited clinician familiarity, competition from established drugs, absence of head-to-head trials, and reimbursement hurdles.
5. What are the key regulatory hurdles facing BARHEMSYS development?
Future approvals outside the U.S. depend on local clinical data and regulatory review. Maintaining safety through post-market surveillance remains essential.
Sources:
- FDA. FDA approval package for BARHEMSYS, 2020.
- Research and Markets. Global Anti-nausea Market Outlook, 2022.
- Evaluate Pharma. Market forecasts for antiemetic drugs, 2022.
